A DNA Topoisomerase II-independent Route for Novobiocin-mediated Resistance to DNA Binding Agents

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1990 Jan 1

PMID 2164457

Authors

P J Smith

S M Bell

Affiliations

Soon will be listed here.

Abstract

The coumermycin antibiotic novobiocin is currently under investigation as an agent that can modify the toxicity of various anti-cancer drugs, potentially via one of its many pharmacological effects: namely, the interference with type II DNA topoisomerase function. This paper investigates the ability of novobiocin to modify the cellular/nuclear accumulation and toxicity of two types of DNA binding agents (the minor groove ligand Hoechst 33342 and the intercalating anthracycline Adriamycin). We report that novobiocin reduces the cytotoxicity of both agents and that this can be attributed to a reduction in cellular and, consequently, nuclear accumulation of these agents rather than to any effect on cellular export. The antibiotic was also active (at non-toxic concentrations) in delaying the progression of cells into S phase and G2 phase. This potential for novobiocin to effect rescue from toxicity by disturbance of the delivery of a drug to a potentially important intracellular target, together with the provision of an extended period of cellular recovery prior to the commitment of cells to G2 + M phase, should be recognised in the design of combination chemotherapy.

References

Sealy L, Cotten M, Chalkley R . Novobiocin inhibits passive chromatin assembly in vitro. EMBO J. 1986; 5(12):3305-11. PMC: 1167327. DOI: 10.1002/j.1460-2075.1986.tb04644.x. View

Glisson B, Ross W . DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther. 1987; 32(2):89-106. DOI: 10.1016/0163-7258(87)90054-4. View

Bachur N, Gordon S, Gee M, Kon H . NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A. 1979; 76(2):954-7. PMC: 383104. DOI: 10.1073/pnas.76.2.954. View

Zimmer C, Wahnert U . Nonintercalating DNA-binding ligands: specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material. Prog Biophys Mol Biol. 1986; 47(1):31-112. DOI: 10.1016/0079-6107(86)90005-2. View

Epstein R, Watson J, Smith P . Subpopulation analysis of drug-induced cell-cycle delay in human tumor cells using 90 degrees light scatter. Cytometry. 1988; 9(4):349-58. DOI: 10.1002/cyto.990090412. View

LATT S, Stetten G . Spectral studies on 33258 Hoechst and related bisbenzimidazole dyes useful for fluorescent detection of deoxyribonucleic acid synthesis. J Histochem Cytochem. 1976; 24(1):24-33. DOI: 10.1177/24.1.943439. View

Morgan S, Watson J, Twentyman P, Smith P . Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer. Br J Cancer. 1989; 60(3):282-7. PMC: 2247179. DOI: 10.1038/bjc.1989.271. View

Smith P, Nakeff A, Watson J . Flow-cytometric detection of changes in the fluorescence emission spectrum of a vital DNA-specific dye in human tumour cells. Exp Cell Res. 1985; 159(1):37-46. DOI: 10.1016/s0014-4827(85)80035-5. View

Eder J, Teicher B, Holden S, Cathcart K, Schnipper L . Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest. 1987; 79(5):1524-8. PMC: 424429. DOI: 10.1172/JCI112983. View

10.

Debenham P, Webb M . Dominant mutation in mouse cells associated with resistance to Hoechst 33258 dye, but sensitivity to ultraviolet light and DNA base-damaging compounds. Somat Cell Mol Genet. 1987; 13(1):21-32. DOI: 10.1007/BF02422296. View

11.

Iliakis G, Lazar W . Reduction by caffeine of adriamycin-induced cell killing and DNA damage in Chinese hamster cells: correlation with modulation in intracellular adriamycin content. Cancer Res. 1987; 47(9):2224-9. View

12.

Downes C, Ord M, Mullinger A, Collins A, Johnson R . Novobiocin inhibition of DNA excision repair may occur through effects on mitochondrial structure and ATP metabolism, not on repair topoisomerases. Carcinogenesis. 1985; 6(9):1343-52. DOI: 10.1093/carcin/6.9.1343. View

13.

Smith P . Relationship between a chromatin anomaly in ataxia-telangiectasia cells and enhanced sensitivity to DNA damage. Carcinogenesis. 1984; 5(10):1345-50. DOI: 10.1093/carcin/5.10.1345. View

14.

Drlica K, FRANCO R . Inhibitors of DNA topoisomerases. Biochemistry. 1988; 27(7):2253-9. DOI: 10.1021/bi00407a001. View

15.

Schwartz H . A fluorometric assay for daunomycin and adriamycin in animal tissues. Biochem Med. 1973; 7(3):396-404. DOI: 10.1016/0006-2944(73)90060-4. View

16.

Gellert M, ODea M, Itoh T, Tomizawa J . Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci U S A. 1976; 73(12):4474-8. PMC: 431506. DOI: 10.1073/pnas.73.12.4474. View

17.

Wang J . DNA topoisomerases. Annu Rev Biochem. 1985; 54:665-97. DOI: 10.1146/annurev.bi.54.070185.003313. View

18.

Smith P, Debenham P, Watson J . A role of DNA topoisomerases in the active dissociation of DNA minor groove-ligand complexes. A flow cytometric study of inhibitor effects. Mutat Res. 1989; 217(2):163-72. DOI: 10.1016/0921-8777(89)90068-2. View

19.

Smith P, ANDERSON C . Modification of the radiation sensitivity of human tumour cells by a bis-benzimidazole derivative. Int J Radiat Biol Relat Stud Phys Chem Med. 1984; 46(4):331-44. DOI: 10.1080/09553008414551511. View

20.

Ganapathi R, Grabowski D, Schmidt H, Yen A, Iliakis G . Modulation of adriamycin and N-trifluoroacetyladriamycin-14-valerate induced effects on cell cycle traverse and cytotoxicity in P388 mouse leukemia cells by caffeine and the calmodulin inhibitor trifluoperazine. Cancer Res. 1986; 46(11):5553-7. View